Clinical Trial Update: Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating nebulized mesenchymal stem cell-derived exosomes for safety and efficacy in Anti-MDA5-positive dermatomyositis-associated ra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Interstitial Lung Disease

Drugs mentioned

• Nebulized MSC-Exos

Snippet

Sponsor: Li Shiyue | Conditions: Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD, Rapidly Progressive Interstitial Lung Disease | Phase 1 | Status: RECRUITING